RxDoctor Payments Data

Simona Braun, MD

Rheumatology · Eugene, ORNPI 1972677045

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (56.3%), consulting fees and education — rather than concentrated in one kind of arrangement. 8 manufacturers reported payments, led by Johnson & Johnson at 45.2% of the total. Reporting peaked in 2019 at $1,109 and has fallen 82.3% since, to $196 in 2023.

$1,405in general payments, 2019–2025

Across 22 payments — averaging $63.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$636
  • AstraZeneca$221
  • GSK$215
  • Amgen$130
  • AbbVie$129
  • Pfizer$47
  • plus $27 from 2 others

What the payments were for

  • Consulting fees$56040%
  • Food & beverage$79156%
  • Education$534%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Johnson & Johnson4$636
AstraZeneca2$221
GSK3$215
Amgen6$130
AbbVie2$129
Pfizer3$47
Novartis1$15
Merck1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,405 in reported general payments places this provider in the 70th percentile of 79 rheumatology providers in Oregon.

See all rheumatology providers in Oregon

Medicare billing

Part B allowed, 2024
$96,374
Medicare patients
216
Services billed
3,649

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Enbrel SureclickEtanercept36$257,580
Humira(Cf) PenAdalimumab17$152,203
EnbrelEtanercept15$109,310
RinvoqUpadacitinib11$68,390
Hydroxychloroquine Sulfate124$5,853
Leflunomide44$4,647
MethotrexateMethotrexate Sodium115$3,240
Sulfasalazine DrSulfasalazine26$1,351
Mycophenolate Mofetil11$955
Sulfasalazine17$924
Prednisone85$641
Folic Acid46$569
Celecoxib13$392
Alendronate Sodium34$335
Omeprazole12$109

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenEnbrel$130$109,31015 claims
AbbVieRinvoq$129$68,39011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 79 rheumatology providers in Oregon.

Other rheumatology in Eugene

See the full list for Oregon

Where these figures come from

Is this you, or does something look wrong? →